Three cardiometabolic-related news items have been observed: Novo initiated a Ph3 study evaluating zenagamtide for ASCVD (view EUClinicalTrials record); Novo has entered into an asset purchase agreement with Kallyope to acquire three novel obesity drug programs (view LinkedIn post); and Sandoz received Health Canada approval for its generic semaglutide (view press release). Below, FENIX provides highlights and insights for the respective news items.